Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03733067|
Recruitment Status : Recruiting
First Posted : November 7, 2018
Last Update Posted : December 17, 2018
CTLA4 stands for cytotoxic T-lymphocyte antigen-4. It is a protein the body makes naturally to check its immune system from attacking itself. Some people don t produce enough CTLA4 protein, causing problems due to overactive immune system such as big spleens, repeated lung infections, breathing problems, stomach and intestine symptoms as well as inflamed brain and nerve problems. Many have problems with their bone marrow causing low numbers of blood cells like platelets, red blood cells or white blood cells, which is called cytopenia. Researchers want to see if the drug abatacept can treat cytopenias by replacing the missing protein CTLA4.
To see if abatacept is safe and helps treat cytopenias caused by CTLA4 deficiency.
People ages 8-65 years who have CTLA4 deficiency with cytopenia
Participants will be screened with medical history, medication review, physical exam and blood and urine tests. They will continue their current medications and may start taking antibiotics daily. Participants will receive either abatacept or placebo through a vein for 6 months. The study team will not know if you are receiving the study drug or the placebo
Women who can become pregnant must agree to use birth control measures.
Men who get someone pregnant during the study will be asked to collect information and have the partner contact the study team.
Participants will undergo the following procedures before starting the study and at the completion:
- radiology scans of body and brain
- heart and lung function tests
- Bone marrow examination by a needle inserted into the hip bone to remove a small amount of tissue to study.
- Participants may have a small camera on a long, thin tool passed down the throat into the stomach and small intestine for evaluation of their gut.
- Questionnaires about their disease, symptoms and quality of life
Over 6 months, participants will have regular study visits and get 8 doses of the study drug or a placebo by intravenous injection. They will repeat some of the same tests done earlier at the end of the study at assess response.
About 1 month after the last study drug visit, participants will have a final study visit.
Some participants may join a treatment extension for the study drug abatacept with no placebo. They will sign a separate consent form for this.
|Condition or disease||Intervention/treatment||Phase|
|CTLA4 Haplonisufficiency Chronic Cytopernia||Drug: Orencia (abatacept) Other: Placebo||Phase 1 Phase 2|
Rare heterozygous mutations in cytotoxic T-lymphocyte antigen-4 (CTLA4) lead to a monogenetic defect that presents with a heterogeneous clinical phenotype of recurrent infections, lymphoproliferation, autoimmunity, and lymphocytic infiltration of target organs. Management is challenging and focuses on treating infections, autoimmune complications, and end organ damage due to lymphocytic infiltrates. Experience with the natural history of the disease and therapies for underlying complications are limited. There is no established standard of care for these patients.
Abatacept is a biologically engineered CTLA4-mimetic that is approved as an intravenous (IV) infusion to treat adult rheumatoid arthritis, adult psoriatic arthritis, and juvenile idiopathic arthritis. Given that abatacept mimics CTLA4 function, we hypothesize that the drug will prevent T-cell hyper-activation, restore regulatory T-cell function, and thereby treat the autoimmune and immune dysregulatory manifestations of CTLA4 deficiency.
This study is a phase 1/2, double-blind, randomized, intra-patient dose-escalation, placebo-controlled trial designed to evaluate the safety and efficacy of abatacept in participants with CTLA4 deficiency and cytopenia. Participants will come to the NIH Clinical Center
monthly for 210 days to receive infusions of study agent or placebo and to undergo safety and research evaluations, including blood draw for cytopenia evaluation and scoring of disease severity. Before and after the treatment period, participants will also have imaging, pulmonary function testing, bone marrow biopsy, and endoscopy (symptomatic participants only). Primary endpoints will be evaluated at Day 210. After completing the blinded treatment trial, participants will be offered the option to enroll in a 6-month open-label extension study for long-term safety evaluation of abatacept.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Abatacept for Treating Chronic Cytopenias in Cytotoxic T-lymphocyte Antigen-4 (CTLA4) Haploinsufficiency|
|Estimated Study Start Date :||December 20, 2018|
|Estimated Primary Completion Date :||July 31, 2025|
|Estimated Study Completion Date :||June 30, 2026|
During the initial treatment period (Days 0,15, and 30) participants will receive FDA-approved doses determined by participant age and weight. Upon dose escalation from Day 60 through Day 180, participants will receive two infusions of the approved dose 18 to 48 hours apart, resulting in a doubled dose. The same dose regimen will be repeated during the open-label extension between Days 210 and Day 390.
Drug: Orencia (abatacept)
Abatacept is supplied as a sterile, white, preservative-free lyophilized powder for reconstruction and dilution. It should be reconstituted according to the package insert, with 10 mL of Sterile Water for Injection, USP, using an 18-to 21 gauge needle and only the silicone free disposable syringe provided with each bottle; solutions prepared using siliconized syringes may develop translucent particles and should be discarded. After reconstitution, abatacept is clear, colorless-to-pale yellow, and free of particulate matter. To conceal the color, the drug will be covered in amber bags and te tubing will be covered. Abatacept should be administered by IV infusion over 30 minutes with and infusion set and a sterile, non-pyrogenic, low-protein-binding filter (pore size of 0.2-1.2 micro m), as described in the package insert. Doses will be determined by participant age and weight.
Placebo Comparator: 2
Administered at the same dosage, frequency, and duration as abatacept between Days 0 and 180. The same dose regimen from Arm 1 will be repeated during the open-label extension between Days 210 and Day 390, except with Orencia (abatacept).
Saline packaged identically to abatacept, with volume matching that of the abatacept dosing by weight, and will be administered via IV infusion identically to abatacept
- All safety parameters (including possibly to definitely related adverse events (AEs) and serious AEs (SAEs), physical exam, vital signs, electrocardiogram (ECG), safety laboratories (hematology, blood chemistry, urinalysis) and incidence and sev... [ Time Frame: Timepoints from first dose of Abatacept until Day 210 ]
- A complete response defined by the normalization of all listed hematologic parameters: A) ANC >1000 cells/microL and B) Platelet count > 100,000 cells/microL and C) Hemoglobin > 10 g/dL. Parameters will be measured at Day 210 and mus... [ Time Frame: Timepoints from Baseline to Day 210. ]
- Partial hematologic response defined as an improvement in one or more of the listed parameters but not meeting complete hematologic response: A) ANC: a 100% increase from baseline or an ANC greater than or equal 750 cells/microL. B) Platelet: fo... [ Time Frame: Timepoints from Baseline to Day 210. ]
- From initiating the taper or discontinuation of concomitant medications, the number of days before a participant meets inclusion criteria for hematologic abnormalities through Day 210. [ Time Frame: Initiation of taper or discontinuation of concomitant medications from Day 120 to 210. ]
- Improvement in PROMIS 10 from Baseline to Day 210. Improvement in patient global assessment from Baseline to Day 210. Improvement in levels of LDH, CRP, ESP, reticulocyte count, haptoglobin, soluble CD25 from Baseline to Day 210. Change in... [ Time Frame: Timepoints from Baseline to Day 210. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03733067
|Contact: Susan M Price, R.N.||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 firstname.lastname@example.org|
|Principal Investigator:||Gulbu Uzel, M.D.||National Institute of Allergy and Infectious Diseases (NIAID)|